Complement and thrombosis in the antiphospholipid syndrome

Autoimmunity Reviews

Volumn 15, Issue 10, 2016, Pages 1001-1004

  Oku, Kenji ^a   Nakamura, Hiroyuki ^a   Kono, Michihiro ^a   Ohmura, Kazumasa ^a   Kato, Masaru ^a   Bohgaki, Toshiyuki ^a   Horita, Tetsuya ^a   Yasuda, Shinsuke ^a   Amengual, Olga ^a   Atsumi, Tatsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti C1q antibody; Antiphospholipid antibody; Antiphospholipid syndrome; Complement pathway

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; REVIEW; THROMBOSIS; ANIMAL; BLOOD; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; THROMBOSIS;

EID: 84990238596     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.020     Document Type: Review

References (28)

1. [1] van den Hoogen, L.L., van Roon, J.A., Radstake, T.R., et al. Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev 15:1 (2016), 50–60.
2. [2] Girardi, G., Berman, J., Redecha, P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112:11 (2003), 1644–1654.
3. [3] Girardi, G., Redecha, P., Salmon, J.E., Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10:11 (2004), 1222–1226.
4. [4] Chenoweth, D.E., Hugli, T.E., Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol 17:2 (1980), 151–161.
5. [5] Skokowa, J., Ali, S.R., Felda, O., et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 174:5 (2005), 3041–3050.
6. [6] Viall, C.A., Chamley, L.W., Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev 14:5 (2015), 446–471.
7. [7] Alijotas-Reig, J., Ferrer-Oliveras, R., Ruffatti, A., et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14:5 (2015), 387–395.
8. [8] Speth, C., Rambach, G., Wurzner, R., et al. Complement and platelets: mutual interference in the immune network. Mol Immunol 67:1 (2015), 108–118.
9. [9] Pierangeli, S.S., Girardi, G., Vega-Ostertag, M., et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52:7 (2005), 2120–2124.
10. [10] Oku, K., Atsumi, T., Bohgaki, M., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:6 (2009), 1030–1035.
11. [11] Chenoweth, D.E., Cooper, S.W., Hugli, T.E., et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304:9 (1981), 497–503.
12. [12] Belmont, H.M., Hopkins, P., Edelson, H.S., et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 29:9 (1986), 1085–1089.
13. [13] Kim, D.D., Song, W.C., Membrane complement regulatory proteins. Clin Immunol 118:2–3 (2006), 127–136.
14. [14] Gropp, K., Weber, N., Reuter, M., et al. beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 118:10 (2011), 2774–2783.
15. [15] Foltyn Zadura, A., Memon, A.A., Stojanovich, L., et al. Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis. J Rheumatol 42:10 (2015), 1786–1793.
16. [16] Lu, J.H., Teh, B.K., Wang, L., et al. The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol 5:1 (2008), 9–21.
17. [17] Arfors, L., Lefvert, A.K., Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti-phospholipid syndrome (APLS). Clin Exp Immunol 108:1 (1997), 47–51.
18. [18] Samarkos, M., Davies, K.A., Gordon, C., et al. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford) 40:9 (2001), 1026–1032.
19. [19] Guerin, J., Casey, E., Feighery, C., et al. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity 31:2 (1999), 109–116.
20. [20] Amengual, O., Atsumi, T., Khamashta, M.A., et al. IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al. Arthritis Rheum 41:8 (1998), 1513–1515.
21. [21] Paidassi, H., Tacnet-Delorme, P., Garlatti, V., et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 180:4 (2008), 2329–2338.
22. [22] Paidassi, H., Tacnet-Delorme, P., Verneret, M., et al. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol Biol 408:2 (2011), 277–290.
23. [23] Martin, M., Leffler, J., Blom, A.M., Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem 287:40 (2012), 33733–33744.
24. [24] Oku, K., Amengua, O., Hisada, R., et al. Autoantibodies against complement component 1 q subcomponent (C1q) contribute to complement activation and recurrent thrombosis/pregnancy morbidity in antiphospholipid syndrome. Rheumatology (Oxford) 55:8 (Aug 2016), 1403–1411, 10.1093/rheumatology/kew196 http://www.ncbi.nlm.nih.gov/pubmed/27084309.
25. [25] Trendelenburg, M., Lopez-Trascasa, M., Potlukova, E., et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 21:11 (2006), 3115–3121.
26. [26] Katsumata, Y., Miyake, K., Kawaguchi, Y., et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 63:8 (2011), 2436–2444.
27. [27] Kallenberg, C.G., Anti-C1q autoantibodies. Autoimmun Rev 7:8 (2008), 612–615.
28. [28] Garlatti, V., Chouquet, A., Lunardi, T., et al. Cutting edge: C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain. J Immunol 185:2 (2010), 808–812.